<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03551002</url>
  </required_header>
  <id_info>
    <org_study_id>IN-US-334-4481</org_study_id>
    <secondary_id>171954</secondary_id>
    <nct_id>NCT03551002</nct_id>
  </id_info>
  <brief_title>Impact of DAA Uptake in Controlling HCV Epidemic and Modeling Interventions for HCV Elimination Among HIV-infected Persons in San Diego</brief_title>
  <official_title>Impact of Direct Acting Antivirals Uptake in Controlling Hepatitis C Epidemic and Modeling Interventions for Hepatitis C Elimination Among HIV-infected Persons in San Diego</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of California, San Diego</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of California, San Diego</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      A retrospective and prospective study among people living with HIV (PLWH) that assesses
      hepatitis C (HCV) treatment uptake during periods before and after direct acting antivirals
      (DAA) introduction, and its impact on the HCV epidemic among PLWH.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      A study that aims to quantify the state of DAA uptake and its impact on the HCV epidemic
      among PLWH in San Diego, and to characterize negative predictors of DAA treatment uptake
      among PLWH in San Diego. Retrospective and prospective data from UCSD Owen Clinic will be
      utilized to calculate HCV prevalence, primary incidence, and reinfection incidence. Using
      mathematical epidemic models, the study will assess levels of existing and scaled-up
      interventions necessary for HCV elimination from PLWH in San Diego.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">January 1, 2018</start_date>
  <completion_date type="Anticipated">December 31, 2020</completion_date>
  <primary_completion_date type="Anticipated">December 31, 2020</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Other</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Annual proportion of HIV-infected patients who initiate direct acting antivirals</measure>
    <time_frame>2014-2020</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Annual proportion of PLWH co-infected with HCV who are treatment naïve, previously treated with no sustained virologic response (SVR), or re-infected post-SVR</measure>
    <time_frame>2008-2020</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Annual HCV chronic prevalence, primary incidence, and reinfection incidence among HIV-infected patients</measure>
    <time_frame>2008-2020</time_frame>
  </secondary_outcome>
  <other_outcome>
    <measure>Estimated HCV prevalence and incidence among PLWH in San Diego using dynamic transmission modeling calibrated to epidemiological data from outcomes described above</measure>
    <time_frame>2008-2030</time_frame>
  </other_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Anticipated">450</enrollment>
  <condition>Hepatitis C</condition>
  <condition>Hepatitis C, Chronic</condition>
  <condition>HIV/AIDS</condition>
  <arm_group>
    <arm_group_label>Retrospective</arm_group_label>
  </arm_group>
  <arm_group>
    <arm_group_label>Prospective</arm_group_label>
  </arm_group>
  <biospec_retention>Samples Without DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      For patients who fail direct acting antivirals (DAA) therapy, a blood sample will be
      collected to conduct phylogenetic analysis
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        People living with HIV, with history of or current HCV infection, who receive care at the
        UCSD Owen Clinic from 2008 to 2020
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Any adult (≥ 18 years) HIV-infected patient attending the UCSD Owen Clinic

          -  With history of acute or chronic HCV infection defined as having a detectable HCV
             viral load with or without a positive HCV antibody

        Exclusion Criteria:

          -  With no history of or current HCV infection defined as having a negative HCV antibody
             from 2008 to 2020
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Edward Cachay, MD, MAS</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of California, San Diego</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Edward Cachay, MD, MAS</last_name>
    <phone>(619)543-3882</phone>
    <email>ecachay@ucsd.edu</email>
  </overall_contact>
  <location>
    <facility>
      <name>Owen Clinic-University of California, San Diego</name>
      <address>
        <city>San Diego</city>
        <state>California</state>
        <zip>92103-8186</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Edward Cachay, MD, MAS</last_name>
      <email>ecachay@ucsd.edu</email>
    </contact>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>September 2019</verification_date>
  <study_first_submitted>May 23, 2018</study_first_submitted>
  <study_first_submitted_qc>May 23, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">June 11, 2018</study_first_posted>
  <last_update_submitted>September 9, 2019</last_update_submitted>
  <last_update_submitted_qc>September 9, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">September 10, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of California, San Diego</investigator_affiliation>
    <investigator_full_name>Edward Cachay, MD, MAS</investigator_full_name>
    <investigator_title>Associate Professor of Clinical Medicine</investigator_title>
  </responsible_party>
  <keyword>HIV</keyword>
  <keyword>Hepatitis C</keyword>
  <keyword>Direct acting antivirals</keyword>
  <keyword>Hepatitis C modeling</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hepatitis A</mesh_term>
    <mesh_term>Hepatitis C</mesh_term>
    <mesh_term>Hepatitis C, Chronic</mesh_term>
    <mesh_term>Hepatitis</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

